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Although specific microRNAs (miRNAs) can be
upregulated in cancer, global miRNA downregulation
is a common trait of human malignancies. The mech-
anisms of this phenomenon and the advantages it
affords remain poorly understood. Here we identify
a microRNA family, miR-103/107, that attenuates
miRNAbiosynthesis by targetingDicer, a key compo-
nent of the miRNA processing machinery. In human
breast cancer, high levels ofmiR-103/107 are associ-
atedwithmetastasis andpooroutcome.Functionally,
miR-103/107 confer migratory capacities in vitro and
empower metastatic dissemination of otherwise
nonaggressive cells in vivo. Inhibition of miR-103/
107 opposes migration and metastasis of malignant
cells. At the cellular level, a key event fostered by
miR-103/107 is induction of epithelial-to-mesen-
chymal transition (EMT), attained by downregulating
miR-200 levels. These findings suggest a new
pathway by which Dicer inhibition drifts epithelial
cancer toward a less-differentiated, mesenchymal
fate to foster metastasis.INTRODUCTION
microRNAs (miRNAs) are an evolutionarily conserved group of
small RNAs (18–24 nucleotides) that inhibit gene expression.
miRNAs are transcribed by RNA polymerase II as longer precur-
sors and then processed into mature miRNAs by the sequential
action of Drosha and Dicer endonucleases (Bartel, 2009). Mature
miRNAs operate via sequence-specific interactions with the 30
untranslated region (UTR) of cognate mRNA targets, causingsuppression of translation and mRNA decay (Ambros, 2004;
Bartel, 2009).
miRNAs coordinate the expression of entire sets of genes,
shaping the mammalian transcriptome (Bartel, 2009). Loss of
miRNA biosynthesis, as in Dicer knockouts, is lethal, owing to
mitotic catastrophe and severely defective stem cell proliferation
and differentiation (Bernstein et al., 2003; Fukagawa et al., 2004;
Tang et al., 2007).
A large body of evidences suggests that the multigene regula-
tory capacity of miRNAs is dysregulated and exploited in cancer:
miRNA loci are targeted by genetic and epigenetic defects, and
miRNA ‘‘signatures’’ have been found informative for tumor
classification and clinical outcome (Calin and Croce, 2006;
Ventura and Jacks, 2009).
Although several miRNAs are upregulated in specific tumors
(Volinia et al., 2006), a global reduction of miRNA abundance
appears a general trait of human cancers, playing a causal role
in the transformed phenotype (Kumar et al., 2007; Lu et al.,
2005; Ozen et al., 2008). However, little is known on the under-
lying mechanisms or the phenotypic advantages afforded to
cells by reduced miRNA expression and, if any, on the clinical
relevance of this phenomenon. The present work sheds light
on these questions as here we identify a microRNA family,
miR-103/107, whose expression is associated with metastasis
and poor outcome in breast cancer patients.miR-103/107 inhibit
the expression of Dicer, causing global microRNA downregula-
tion. miR-103/107 foster the acquisition of mesenchymal
characteristics and are relevant for breast cancer cell migration
and metastatic dissemination.
RESULTS
miR-103/107 Target Dicer
miRNAs constrain gene expression by binding to the 30UTR of
messenger RNA (mRNAs); thus, genes that must remain activeCell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc. 1195
Figure 1. miR-103/107 Target Dicer
(A) Schematic representation of the 30UTR of Dicer. Red
bars show predicted miR-103/107 target sequences.
Below, sequences of mature miR-103 and miR-107
aligned to one of these target sites, revealing evolutionary
conservation in the seed-pairing sequence between
amphibians (Xenopus, Xtr), birds (Gallus, Gga), and
mammals (human, Hsa and mouse, Mmu).
(B) Schematic representation of the reporters formiR-103/
107 activity against the Dicer 30UTR. The CMV promoter
drives constitutive transcription of a chimeric mRNA
containing the firefly luciferase coding sequence fused to
the full-length Dicer 30UTR (Lux-Dicer-30-WT) or to the
same UTR mutated in all the miR-103/107 seed-pairing
sequences (Lux-Dicer-30-MUT). Below, the predicted
miR-103/107-binding sites in the 30UTR of Dicer mRNA
are responsive to endogenous (compare lane 1 with lane
5) and overexpressed miR-103 or miR-107 in human
U2OS cells. Luciferase reporters were transfected in
parental () or in stable cell lines expressing pri-miR-
103, pri-miR-107, or, as a control, the unrelated pri-miR-
154. Absolute values are shown as mean and standard
deviation (SD).
(C) Downregulation of endogenous Dicer protein expres-
sion by miR-103/107 as assayed by immunoblotting.
LaminB serves as loading control. Controls are shGFP
(U2OS) or scrambled siRNA (MDA-MB-231). Mature
miR-107-MUT bears mutations in the seed sequence
and is inactive compared to wild-type.
(D and E) Endogenous requirement of miR-103/107 as
Dicer inhibitors. In (D), bars show expression of the
Dicer 30UTR reporters in cells depleted of endogenous
miR-103/107 by treatment with antagomiR. Values relative
to antagomiR-MUT-treated cells are shown as mean and
SD. Effectiveness and specificity of antagomiR treatments
on endogenous miR-103/107 expression are shown in
Figure S1D. In (E), endogenous Dicer protein levels are
upregulated in miR-103/107-depleted cells.
(F) In line with its effect on Dicer, overexpression of
miR-107 causes a global reduction of mature miRNAs
endogenously expressed in MDA-MB-231 cells. Dots
show the ratio of miRNAs expression levels in miR-107
versus miR-107-MUT transfected cells. Global miRNA
expression was measured with TaqMan Human miRNA
Array and normalized to snRNA-U6b loading control.
See Table S1 for expression values.
(G) Expression of a miR-103/107-insensitive Dicer cDNA rescues mature miRNA expression, here exemplified by miR-15a. The effects of miR-107 on mature
miR-15a levels were compared in parental and MDA-MB-231 cells stably expressing a miR-103/107-insensitive form of Dicer (+Dicer). miR-15a expression
was measured by qRT-PCR and normalized to snRNA-U6b loading control. Relative values are shown as mean and SD.
See also Figure S1 and Table S1.across different cell types, such as housekeeping genes, typi-
cally evolved 30UTRs that are short, allowing them to escape
this regulation (Bartel, 2009). During a survey of the 30UTRs of
several housekeeping genes, we were struck by the unusual
length of the 30UTR of Dicer (>4000 bp). As Dicer is essential
for processing miRNA precursors (Filipowicz et al., 2008), this
raised the possibility that some mature miRNAs could feed
back to control Dicer expression. To explore this further, we
used Pictar and TargetScan computational tools (Friedman
et al., 2009; Krek et al., 2005) to search for miRNA binding sites
in the 30UTR of Dicer. From this analysis, the miR-103/107 family
(composed ofmiR-103.1, miR-103.2, andmiR-107) stood out for
the presence of eight evolutionarily conserved binding sites,1196 Cell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc.suggesting cooperative binding and biologically effective inter-
action (Figure 1A).
To test ifmiR-103/107 target Dicer, we first generated reporter
constructs in which the full-length 30UTR ofDicer, either wild-type
or mutant in the miR-103/107-binding sites, was cloned down-
stream of the luciferase open reading frame (Lux-Dicer-30-WT
or -MUT, respectively, Figure 1B). The activity of these two
reporters was compared in human U2OS cells: the wild-type
reporter showed a reduced expression compared to its mutant
version, as expected if the endogenous miR-103/107 were pair-
ing to the predicted binding sites (Figure 1B, compare lanes 1 and
5). Retroviral transduction of either pri-miR-103 or pri-miR-107
expression vectors caused further inhibition of the wild-type
30UTR reporter (Figure 1B, compare lane 5 with lanes 6 and 7) but
not of the corresponding seed mutant reporter. As control, forced
expression of the unrelated pri-miR-154 or shGFP had no effect
on luciferase expression (Figure 1B, lane 8). Collectively, these
data indicate that miR-103/107 target the Dicer 30UTR.
We next monitored to what extent miR-103/107 affect the
endogenous levels of Dicer protein. In multiple cell lines, Dicer
protein was specifically downregulated (about 50%–60% reduc-
tion) by expressing pri-miR-103 or pri-miR-107 (Figure 1C, left
panel and Figure S1A available online). To exclude any poten-
tially confounding effect from the viral expression system—or
from flanking sequences of the pri-miR constructs—we also
transiently transfected cells with the mature form of miR-107
or, as control, a mutant miR-107 that contained three mis-
matches in the seed-binding sequence (miR-107-MUT). Dicer
protein levels were downregulated by mature miR-107 but not
miR-107-MUT (Figure 1C, right panel and Figure S1B).
miR103/107 affect Dicer levels acting on its 30UTR, as lentiviral
expression of Dicer lacking the 30UTR was insensitive to
miR-107 (Figure S1C).
Next, we tested ifmiR-103/107 are causal for Dicer downregu-
lation in a loss-of-function experimental setting. For this, we
used antagomiR reagents (Krutzfeldt et al., 2005) to silence
endogenous miR-103/107 (antagomiR-103/107); as a control,
we used a mutant version of this reagent carrying six mis-
matches (antagomiR-MUT) (Figure S1D). As shown in Figure 1D,
treatment of MDA-MB-231 cells with antagomiR-103/107
specifically promoted expression of the Dicer 30UTR-wild-type
reporter and, crucially, upregulated endogenous Dicer protein,
as assayed by immunoblotting (Figure 1E). Thus, Dicer levels
are limited by endogenous miR-103/107.
We then investigated the effects of the miR-103/107-Dicer
interaction on miRNA biosynthesis, by comparing miRNAs levels
in MDA-MB-231 cells expressing miR-107 or miR-107-MUT. As
assayed quantitatively by qPCR, mature miRNAs were globally
downregulated in the presence of miR-107, and this is phe-
nocopied by Dicer knockdown (Figure 1F; Figures S1E and
S1F; and Table S1). Sustaining Dicer expression by means of
a miR-107-insensitive transgene rescues this effect (Figure 1G,
Figure S1G, and data not shown).
If miR-103/107 restrict miRNA processing at the level of Dicer,
then the levels of miR-103/107 should directly correlate with the
abundance of Dicer substrate, that is, the 70 nt precursor
miRNAs (pre-miRNAs). Indeed, pre-miRNAs, but not pri-miR-
NAs, accumulate in miR-107-expressing MDA-MB-231 cells
(Figure S1H).
In sum, miR-103/107 lead to inhibition of miRNA biogenesis
through Dicer downregulation.
Inverse Correlation betweenmiR-103/107
and Dicer Levels in Cancer Cell Lines
At this point, we were intrigued by the analogy between the
effects of miR-103/107 on Dicer function and the hampered
maturation of multiple miRNAs observed in human tumors
(Lu et al., 2005; Ozen et al., 2008; Ventura and Jacks, 2009).
Following this lead, we first compared the endogenous levels of
miR-103/107 and Dicer protein in a well-established cellular
model of mammary tumor progression, consisting of fourdistinct cell lines, 67NR, 168FARN, 4TO7, and 4T1, all derived
from a single primary tumor and whose activity as xenografts
reflects the sequence of multistep progression toward
metastasis (Aslakson and Miller, 1992). We found that miR-103/
107 expression levels increased from the nonaggressive cells
(67NR, 168FARN) to metastatic lines (4TO7 and 4T1). Conversely,
endogenous Dicer protein levels decreased in metastatic lines
(Figure 2A). To determine whether the expression of miR-103/
107 increases with enhanced metastatic propensity in another
cellular context, we analyzed SW480 and SW620 human colon
cancer cell lines, derived, respectively, from the primary tumor
and a metastasis of the same patient (Leibovitz et al., 1976). As
shown in Figure 2B, an inverse correlation between miR-103/
107 and Dicer level could also be observed in this case.
Clinical Association ofmiR-103/107 Expression
to Breast Cancer Metastasis and Poor Prognosis
The data on cell lines suggested a possible link between
miR-103/107 expression and tumor progression. We surmised
that, if biologically meaningful, this mechanism might also be
found in human tumors. For this, we measured mature
miR-103/107 levels in a collection of breast cancer patients
treated in our Institution with annotated clinical history. Patients
were divided in two groups, with respectively high or low levels
of miR-103/107 (Figure 2C, see Extended Experimental
Procedures). Remarkably, when tested using the Kaplan-Meier
survival analysis, the miR-103/107 ‘‘high’’ group displayed a
significant higher probability to develop metastasis when com-
pared to the ‘‘low’’ group (Figure 2D). In line with our biochemical
characterization of Dicer as target of miR-103/107, the ‘‘high’’
group tumors showed a reduced level of Dicer protein when
compared to the ‘‘low’’ group, as assayed by immunohistoche-
misty (Figures 2E–2H).
We next wished to extend these analyses to independent
cohorts of patients. For this, we took advantage of the fact that
miR-103 and miR-107 are intronic miRNAs contained in three
PANK (Pantothenate kinase) loci of the human genome (i.e.,
PANK1, 2, and 3 corresponding to pri-miR-107, pri-miR-103-2,
and pri-miR-103-1, respectively). Expressions of PANK genes
paralleled that ofmiR-103/107 in the series of cell lines described
above (Figure S2); this coexpression is in line with a previous
analysis in normal human tissues (Baskerville and Bartel, 2005).
We thus used PANK/pri-miR-103/107 expression as an
approximation of miR-103/107 levels to interrogate several
public gene expression datasets for which a wealth of molecular
and associated clinical data is available (summing up to more
than 1000 breast cancer patients, see Extended Experimental
Procedures). For each dataset, tumors were divided in two
groups, with respectively high or low levels of pri-miR-103/107
(see Extended Experimental Procedures for details). In agree-
ment with our previous analyses on mature miR-103/107, the
group expressing higher levels of pri-miR-103/107 displayed
a significantly higher probability to develop metastasis and
poor outcome when compared to the ‘‘low’’ group (Figure 2I
and Figure S3). Taken together, our results suggest that high
miR-103/107 expression is unlikely to represent a general
feature of all tumors but rather identifies those associated to
adverse and metastatic disease.Cell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc. 1197
Figure 2. Clinical Association ofmiR-103/107 with
Metastasis in Breast Cancer Patients
(A and B) Top panels: Expression of miR-103/107
increases in cellular models of metastasis progression,
as assayed by qRT-PCR. Values relative to the nonmeta-
static, less aggressive line (67NR and SW480, respec-
tively) are normalized to snRNA-U6b and shown as
mean and SD. Lower panels: Western blot for Dicer
showing the inverse correlation between Dicer protein
levels and miR-103/107 expression. LaminB serves as
loading control. See also Figure S2 for levels of pri-miR-
103/107 in the same samples.
(C and D) Mature miR-103/107 levels predict metastasis
proclivity in breast cancer patients.
(C) Box plots showing the expression levels of mature
miR-103 and miR-107 in breast cancer samples from the
‘‘Milan-INT’’ patients’ dataset (Table S2). Samples were
divided in two groups with coherent low or high expression
of both genes. ‘‘Low’’ and ‘‘High’’ are the names of the two
groups of patients. Each box represents median and 75th
and 25th percentile values.
(D) Kaplan-Meier graph representing the probability of
metastasis-free survival in breast cancer patients from
the ‘‘Milan-INT’’ dataset stratified as in (C). The log-rank
test p value reflects the significance of the association
between high miR-103/107 levels and metastasis.
(E–H) Immunohistochemistry for Dicer protein expression
in primary human breast cancer samples from the
‘‘Milan-INT’’ dataset (analyzed above). Panels show repre-
sentative pictures of Dicer staining in normal breast tissue
(E) or cancer tissues with low (F) or high (G) levels of
miR-103/107 (‘‘Low’’ and ‘‘High’’ groups, respectively).
N indicates mammary ducts with normal morphology
(used as internal positive controls for Dicer IHC), whereas
T indicates tumor cells. (H) Percentage of breast cancer
samples (n = 20), from the ‘‘Low’’ and ‘‘High’’ groups,
that display Dicer staining in the cancer tissue comparable
to the adjacent normal tissue (as shown in F).
(I and J) Kaplan-Meier graphs representing the probability
of metastasis-free survival in breast cancer patients from
the ‘‘London’’ dataset (see Extended Experimental Proce-
dures) stratified according to low or high pri-miR-103/107
expression levels (I) or to low and high Dicer expression
levels (J). The log-rank test p values reflect the significance
of the association between high pri-miR-103/107 and
metastatic relapse but fail to show any association for
Dicer. See Figure S3 for similar results obtained from
four other independent breast cancer datasets.Given the significant association between miR-103/107
expression, Dicer protein levels, and clinical relapse, we wished
to establish if a similar association existed for Dicer transcripts.
However, when breast cancer patients’ stratification was
repeated based on high or low Dicer mRNA levels, our analyses1198 Cell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc.failed to detect a significant association with
metastasis or outcome (Figure 2J and Figure S3).
miR-103/107 Downregulate Dicer
to Promote Cell Migration
and Invasion In Vitro
In light of the preceding data, we sought to
determine more directly if the miR-103/107-Dicer connection plays a causal role in conferring aggressive
traits to breast cancer cells. For this, we assayed how gain or
loss of function of either miR-103/107 or Dicer impacted on
cell migration, a hallmark of metastatic capacity. We first as-
sayed 168FARN and SUM149: these cells are tumorigenic but
Figure 3. miR-103/107 Outbalance Dicer to
Promote Cell Migration and Invasion
(A and B) miR-103/107 expression promotes migration in
SUM149 breast cancer cells by attenuating Dicer levels.
Stable cell lines expressing shGFP (lane 1), pri-miR-103
(lane 2), pri-miR-107 (lane 3), and shDicer (lane 4) from
retroviral expression vectors were compared in transwell
migration assays. Lane 5 shows the effect of a miR-insen-
sitive Dicer transgene on migration of cells already ex-
pressing pri-miR-107. (A) absolute quantifications of cells
migrated through the transwell. (B) representative pictures
of cells migrated through the filter, stained with crystal-
violet, taken at the same magnification (53).
(C and D) miR-107 promotes migration of parental
MDA-MB-231 breast cancer cells (Control) but not of cells
expressing miR-insensitive Dicer (+Dicer). Graph in (D)
shows the absolute number of cells invading the wound
for which we provide representative pictures in (C).
(E) Wound-healing assay as in (C) showing how only partial
knockdown of Dicer (lanes 6–8) mimics gain of miR-107 to
promote cell migration. MDA-MB-231 cells were trans-
fected with 2-fold serial dilutions of Dicer siRNA, ranging
from 25 nM (lane 2) to 0.2 nM (lane 9). Graphs show the
absolute number of cells invading the wound.
(F) Immunoblotting of cells transfected as in (E). siDicer
high (25 nM) corresponds to lane 2, siDicer low (0.8 nM)
to lane 7. Note comparable depletion between the latter
and miR-107. b-catenin (b-cat) serves as loading control.
(G) Endogenous miR-103/107 promote cell migration
through Dicer downregulation. Depletion of endogenous
miR-103/107 by treatment with antagomiR-103/107
reduces the migration of 4T1 cells (lanes 1 and 2), without
having effect on proliferation and cell cycle (see Fig-
ure S4E). Stable expression of Dicer similarly opposes
cell migration (lane 3). In contrast, migration of Dicer-
depleted cells (shDicer) is not reduced by treatment with
antagomiR-103/107 (compare lanes 4 and 5). Graphs
show the absolute quantitations of cells invading transwell
filters.
Data are represented as mean and SD. See also Figure S4.display poor migratory capacities and contain relatively low
levels of miR-103/107 (see Figure 2A and data not shown). As
assayed in transwell migration assays, raising miR-103/107 in
these cell lines increased migration by 8- to 10-fold, whereas
overexpression of control-shGFP had no effect (Figure 3A,
compare lane 1 with lanes 2 and 3, Figure 3B. See Figure S4A
for results on 168FARN cells).Cell 141, 119Induction of migratory capacity by miR-103/
107 relies on attenuation of Dicer as expression
of miR-103/107 is phenocopied by shDicer
SUM149 cells (reducing Dicer to about 40%
its normal levels) and is rescued by coexpres-
sion of a miR-insensitive Dicer transgene that
restores Dicer protein to a level near-to-endog-
enous (Figure 3A, lanes 4 and 5, see immuno-
blots in Figure S4C). Similar results were
obtained in wound-healing assays with another,
more aggressive cell line, MDA-MB-231 cells
(Figures 3C and 3D). Thus, miR-103/107
empower cell motility through Dicer inhibition.Complete loss of Dicer is detrimental for cell survival (Fuka-
gawa et al., 2004), whereas here we show that miR-103/107
enhance motility with no effect on cell proliferation (Figures
S4B and S4D). Different degrees of Dicer downregulation may
reconcile these findings, as Dicer protein is only partially down-
regulated by miR-103/107. To tackle this quantitative issue, we
transfected MDA-MB-231 cells with increasing doses of Dicer5–1207, June 25, 2010 ª2010 Elsevier Inc. 1199
Figure 4. miR-107 Induces Metastatic Dissemination
(A and B) Lung colonization assays of SUM149 derivatives after injection in the
tail vein of SCID mice (8 mice per cell line). Four weeks after injection, lungs
were analyzed for the presence of metastatic nodules.
(A) Quantification of metastatic nodules formed by the indicated SUM149
derivatives. Analyses were carried out on histological sections of the lungs
1200 Cell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc.siRNA, inducing a range of depletions, from negligible to more
quantitative knockdown (Figure 3F and data not shown). As
expected, full Dicer knockdown impaired cell viability and,
consequently, secondarily reduced cell migration if compared
to control cells (Figure 3E, compare lane 1 with lanes 2–4).
Remarkably, however, partial attenuation of Dicer to levels
similar to those achieved bymiR-103/107 (i.e., 50%–60% reduc-
tion) potently fostered cell migration (Figure 3E, lanes 6–8 and 10
and Figure 3F). Similar results were obtained with immortalized
mouse mammary epithelial cells NMuMg (Figures S4F–S4H).
These findings suggest that cell migration is exquisitely sensitive
to the levels of Dicer, and that the degree of Dicer downregula-
tion imposed by miR-103/107 is sufficient to unleash aggressive
cell behaviors.
We next tested if endogenous levels of miR-103/107 are
required for cell migration in the highly metastatic tumor cell
line 4T1. For this, we first silenced miR-103/107 by treatment
with antagomiR-103/107. This leads to a 5-fold reduction in
migratory properties similar to that one obtained by increasing
Dicer expression (Figure 3G, lanes 1–3). Strikingly, loss-of-Dicer
renders 4T1 cells insensitive to loss of miR-103/107, indicating
that Dicer is epistatic to miR-103/107 (Figure 3G, compare lanes
1 and 2 with lanes 4 and 5). Taken together, the data suggest that
the balance between miR-103/107 and Dicer is critical to
controlling cancer cell motility.
Expression ofmiR-107 Endows Metastatic Potential
The data presented so far raised the possibility that the link
betweenmiR-103/107 and Dicer could configure in vivo a metas-
tasis-promoter/suppressor pair. To test this idea, we assayed if
miR-103/107 could foster metastasis in vivo. For this, we used
SUM149 cells, which form nonmetastatic primary tumors
in vivo after injection in the mouse mammary gland (Ma et al.,
2007) but retain residual lung colonization capacity when
delivered through the tail vein. Notably, expression of pri-miR-
107, but not shGFP (control), strongly promoted metastatic
colonization (Figure 4A, compare lanes 1 and 2, and Figure 4B).
In agreement with our previous in vitro characterization, this is
phenocopied by partial depletion of Dicer (Figure 4A, lane 3 and
Figure 4B). Conversely, rescuing Dicer expression (Figure S4C)
abolished the prometastatic effects of miR-107 (Figure 4A, lane(4 sections per lung) stained with the anti-cytokeratin antibodies AE1/AE3.
Data are represented as mean and SD.
(B) Representative pictures of metastases embedded in the lung parenchyma.
Macrometastases were observed only in mice injected with cells expressing
pri-miR-107 or shDicer.
(C) SCID mice were orthotopically injected in the fat pad with SUM149-shGFP
or SUM149-miR-107 cells. The rates of primary tumor growth were not
significantly different, showing, if anything, a reduced proliferation of
SUM149-miR-107 in vivo. Data are represented as mean and SD.
(D and E) Pri-miR-107 promotes distant metastatic dissemination of breast
cancer cells from the orthotopic site. Lungs of mice injected in (C) were
explanted after 12 weeks and scored for the presence of metastases as in
(A). (E) Right panel: representative metastatic focus of SUM149-miR-107 cells
embedded in the lung parenchyma. Graphs in (D) provide a quantification of
metastatic dissemination measured as the percentage of sections displaying
at least one metastasis out of n = 8 SUM149-shGFP injected mice and n = 8
SUM149-miR-107 injected mice. Four to six serial sections were sampled
and analyzed for each mouse.
4 and Figure 4B). Thus, Dicer serves as metastasis suppressor
downstream of miR-103/107.
Having established this relationship, we next asked whether
miR-107 would also empower distant metastatic dissemination
from primary tumor masses. For this, we implanted control
(shGFP) andmiR-107-expressing SUM149 cells in the mammary
fat pad of immunocompromised mice. As previously shown
in vitro, gain of miR-107 does not foster proliferation in vivo,
not even within the competitive tumor microenviroment (Fig-
ure 4C). After 12 weeks, host mice were sacrificed and examined
for the presence of metastatic lesions in the lung. Although no
macroscopic metastases were detected, the staining of histo-
logical sections with anti-cytokeratin antibodies revealed the
presence of micrometastatic foci in the lungs explanted from
mice bearing the SUM149-miR-107 xenografts, whereas almost
none were found in mice injected with control cells (Figures 4D
and 4E). Thus, once overexpressed, miR-107 is a prometastatic
factor that unleashes the ability to initiate distant dissemination
in otherwise nonmetastatic cells. Further, these data provide
functional support to the association between miR-103/107
and clinical relapse previously revealed in human tumors.
Silencing ofmiR-103/107 Inhibits Metastasis
We next asked if continuous repression of Dicer by endogenous
miR-103/107 in aggressive cells is required for metastatic
spread in vivo. For this, 4T1 cells were injected into the mammary
fat pad of recipient mice and tumors treated either with antago-
miR-103/107 or antagomiR-MUT (see Experimental Proce-
dures). As shown in Figure 5A, we found that the onset and
size of primary tumors were comparable in the two groups of
mice (p value > 0.05), despite the quantitative loss of endog-
enous mature miR-103/107 in antagomiR-103/107-treated
primary tumors (Figure 5B). Strikingly, however, although the
antagomiR-MUT receiving cells invaded the lung parenchyma,
silencing of miR-103/107 efficiently reduced metastatic coloni-
zation (Figures 5C, 5D, and 5E). This occurred without detectable
detrimental effects on normal mammary glands (Figure S5A).
Thus, endogenousmiR-103/107 is critical for efficient metastatic
dissemination of breast cancer cells.
We also compared control and miR-103/107-depleted
primary tumors for expression of a number of miRNAs. As
expected from the rescue of endogenous Dicer activity, silencing
of miR-103/107 enhanced global miRNA processing, as re-
vealed by the increased levels of mature miRNAs (Figure 5F)
and concomitant reduction of the 70 nt miRNA precursors (Fig-
ure S5B). This suggests that Dicer is limiting in metastatic
tumors.
If the reduction of Dicer activity by high miR-103/107 is critical
for the execution of the metastatic program, then sustaining
Dicer expression should phenocopy the loss of miR-103/107
and oppose metastasis. To test this, we selected two Dicer-
overexpressing 4T1 cell clones from a lentivirally infected cell
population (Figure S5C). Dicer-4T1-derived tumors were strik-
ingly deprived of metastatic capacity when compared to lesions
from mock-infected cells (Figures 5G–5I). In sum, the data reveal
a functional pathway in aggressive tumors, whereby endoge-
nous miR-103/107 are instrumental to attenuating Dicer levels
below a threshold for metastasis protection.Because levels of Dicer are around 50% when miR-103/107
are elevated, one would expect that heterozygous loss of Dicer
would represent one mechanism selected during tumor
progression to favor metastasis. To explore this issue, we
queried array CGH profiling of breast cancers and found that
some tumors display a reduced copy number of the Dicer1
locus, a finding compatible with Dicer heterozygosity; intrigu-
ingly, this subset of tumors also display an increased propensity
to develop metastasis (Figure S5D). This provides a genetic
proof-of-principle that selective pressure for Dicer downregula-
tion exists in aggressive breast cancer. Interestingly, pri-miR-
103/107 expression levels are able to stratify patients according
to outcome only in Dicer+/+ tumors but not upon Dicer heterozy-
gosity (Figure S5E). In other words, Dicer heterozygous tumors
lost selective pressure for miR-103/107 upregulation, support-
ing the notion that these molecules are indeed in the same
pathway. It is, however, remarkable that the number of tumors
displaying elevated miR-103/107 and wild-type Dicer is higher
(37%, n = 313) than those carrying copy-number variations of
the Dicer gene (18%), suggesting that the use of an miRNA is
preferred to genetic deletions, at least in this context (see
Discussion).
miR-103/107 Promote Epithelial-to-Mesenchymal
Transition
We next wished to understand the nature of aggressive cell
behaviors leading to metastatic dissemination empowered by
the miR-103/107-Dicer axis. We found that miR-107 expression
did not significantly affect cell proliferation, growth after serum
starvation, resistance to apoptotic stimuli, and anoikis in immor-
talized mammary cell lines (MCF10A, NMuMG) or tumor cell lines
(SUM149, MDA-MB231) (data not shown). This is in line with our
previous measurements of the growth rates of cancer cells
in vitro and in vivo upon gain or loss of miR-103/107 (Figure 4C,
Figure 5A, and Figures S4B, S4D, and S4E).
In contrast, our attention was attracted by a striking change
in cellular shape promoted by overexpression of miR-107,
whereby the cobblestone-like appearance of epithelial cells
switched to a spindle-, fibroblast-like morphology with extensive
cellular scattering and formation of lamellipodia (Figures 6A and
6B). These are hallmarks of epithelial-to-mesenchymal transi-
tions (EMT). EMT is a pivotal cellular program to induce rapid
changes in the shape and motility of epithelial cells, normally
used during morphogenesis and tissue repair. EMT is also aber-
rantly activated in cancer cells to promote their malignant and
stem cell characteristics (Polyak and Weinberg, 2009). The
aggressive traits conferred by the EMT program to carcinoma
cells presented clear similarities with those empowered by
miR-103/107: both are clinically associated in breast cancer
with poor clinical outcome and are functionally required for
migration, invasion, and metastasis (Polyak and Weinberg,
2009).
To determine if the molecular alterations typical of an EMT
occurred inmiR-107-expressing cells, we examined the localiza-
tion of adherent and tight junction markers, such as E-Cadherin
and ZO-1 in NMuMg cells, a well-established model system for
the study of EMT (Miettinen et al., 1994). Immunofluorescence
showed that these proteins were strongly downregulated in cellsCell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc. 1201
Figure 5. Endogenous Requirement of miR-103/
107 for Metastatic Dissemination
(A) The onset and growth rates of orthotopic 4T1 primary
tumors were not significantly different in the presence
(AntagomiR-MUT) or absence (AntagomiR-103/107) of
miR-103/107 expression. Data are represented as mean
and SD.
(B) AntagomiR-103/107 inhibits miR-103 and miR-107
expression in 4T1-derived primary tumors formed upon
orthotopic injection (fat pad) in SCID mice. Panels show
expression levels of the indicated microRNAs as
measured by qRT-PCR on representative primary tumors
(explanted from mice dubbed #8 to #11), normalized to
snRNA-U6b loading control. Data are represented as
mean and SD of replicas.
(C) Depletion of miR-103/107 reduces metastatic coloni-
zation. Lungs of mice injected in (A) were explanted
after 21 days and scored for the presence of metastases.
Metastatic burden was measured as the average number
of metastatic foci per histological section (H&E stained),
quantifying 10 to 12 serial sections for each mouse, on
n = 10 mice for each regimen. p value was obtained using
a one-sided Student’s t test.
(D and E) Pictures show representative H&E sections of
the lung parenchyma from 4T1 tumor-bearing mice
treated with antagomiR-MUT (D) or antagomiR-103/107
(E). M, metastatic nodule.
(F) In vivo depletion of miR-103/107 enhances miRNA
maturation. Bars show the comparison between expres-
sion of the indicated mature miRNAs in antagomiR-
MUT- versus antagomiR-103/107-treated 4T1 pooled
primary tumors (n = 3 for each treatment), as measured
by qRT-PCR. Relative values are shown as mean and
SD. See Figure S5B for expression levels of the corre-
sponding pre-miRNAs.
(G) Raising Dicer expression reduces metastatic lung
colonization. SCID mice were orthotopically injected in
the fat pad with control 4T1 cells or two independent
Dicer-expressing lines (n = 6 mice for each cell line). Lungs
were explanted after 20 days and scored for the presence
of metastases as in (C).
(H and I) representative H&E sections of the lung paren-
chyma from mice bearing tumors originating from control
4T1 cells (H) or Dicer-expressing 4T1 cells (I).
See also Figure S5.expressingmiR-107 (Figure 6B). EMT was also validated by gene
expression analysis: in the presence of miR-107, expression of
E-Cadherin mRNA was downregulated whereas the mesen-
chymal markers vimentin, ICAM-1, and fibronectin mRNAs
were significantly increased (Figures 6C–6F). In agreement with
the role of Dicer downregulation as mediator of miR-107 effects,
lowering Dicer levels by shRNA similarly caused reduction of
E-Cadherin and induction of vimentin. Thus, the ability to induce
EMT parallels with the previously shown induction of cell motility
by miR-107 or Dicer downregulation (see Figure S4F).
We next asked if modulating the levels of miR-103/107
altered the mesenchymal traits of metastatic cells. For this,1202 Cell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc.we monitored the effects of gain and loss
of miR-103/107 in MDA-MB-231. Gain of
miR-107 massively induced expression of
fibronectin, vimentin, and ICAM (Figure 6G),whereas antagomiR-mediated depletion of endogenous
miR-103/107 reduced expression of the same genes
(Figure 6H).
In line with such an endogenous role of miR-103/107 in EMT,
we found that high versus low levels of pri-miR-103 are associ-
ated with mesenchymal versus epithelial phenotypes in a panel
of breast cancer cell lines previously stratified according to
expression profiles and metastatic capacity (Charafe-Jauffret
et al., 2009) (Figure 6I).
Taken together, the data indicate that expression of miR-103/
107 is sufficient for inducing epithelial plasticity and required for
maintenance of mesenchymal gene expression.
Figure 6. miR-103/107 Induce Epithelial Plasticity
(A) Morphology of MCF10A cells transiently transfected
with mature miR-107 or the control miRNA (miR-107-
MUT). Note the loss of cell-cell adhesion and acquisition
of spindle morphology in cells expressing miR-107.
(B) NMuMG cells were transiently transfected with control
miRNA (miR-107-MUT) or miR-107 and, after 3 days,
analyzed for epithelial characters. Panels show the
bright-field morphology of transfected cells (upper panels)
and the immunofluorescence for the adherent junction
marker E-Cadherin (green, middle panels) or for the tight
junction marker ZO-1 (green, lower panels). Nuclei are
stained in blue with DAPI.
(C–F) Expression of the epithelial marker E-cadherin (D)
and of the mesenchymal markers vimentin (C), fibronectin
(E), and ICAM-1 (F) was examined by qRT-PCR in NMuMG
cells. Graphs show relative expression levels, normalized
to GAPDH. Stable expression of pri-miR-107 by retroviral
transduction, transient transfection of mature miR-107, or
shRNA knockdown of Dicer (shDicer) upregulates mesen-
chymal while inhibiting epithelial markers. miR-107-MUT
and shGFP are negative controls. TGF-beta treatment
(TGFb1 200 pM for 3 days) serves as positive control for
EMT induction. Data are shown as mean and SD.
(G) Transient transfection of mature miR-107 increases
the expression of the mesenchymal markers vimentin,
fibronectin, and ICAM-1 in MDA-MB-231 cells, as quanti-
fied by qRT-PCR. Expression values were given as relative
to those of miR-107-MUT-treated cells. Data are shown as
mean and SD.
(H) Pri-miR-103/107 are required to support mesenchymal
gene expression in MDA-MB-231 cells. Cells were treated
for 5 days with antagomiR-MUT or antagomiR-103/107
and analyzed for mesenchymal markers by qRT-PCR.
For each marker, expression values were given as relative
to those of antagomiR-MUT-treated cells. Data are shown
as mean and SD.
(I) Pri-miR-103 expression correlates with mesenchymal
traits in a panel of breast cancer cell lines. Heatmap
depicts the relative changes of standardized expression
values of E-cadherin, vimentin, and pri-miR-103 for each
cell line. Blue indicates low expression whereas yellow
indicates high expression.miR-103/107ControlMesenchymal Traits by Regulating
the Expression of themiR-200 Family of miRNAs
We next wished to define the identity of key miRNAs acting as
downstream mediators of the miR-103/107-Dicer axis. We
focused on the miR-200 family (Figure 7A) because previous
studies showed that these miRNAs display properties opposite
to those of miR-103/107: they are required to suppress EMT
and migration while their attenuation unleashes mesenchymal
gene expression (Inui et al., 2010; Polyak and Weinberg, 2009).Cell 141, 119If members of the miR-200 family are func-
tionally relevant downstream of miR-103/107,
then miR-200 should oppose miR-107.
Confirming this hypothesis, transfection of
miR-200b in NMuMG cells reverts the EMT
induced by miR-107, as assayed by mor-
phology and gene expression (Figures 7B and
7C). Migration of MDA-MB-231 cells is inhibited
by antagomiR-103/107 but, remarkably, thishas no effect in miR-200-depleted cells (by means of antago-
miR-200, targeting the whole miR-200 family) (Figure 7D).
Biochemically, mature miR-200 levels were increased by
antagomiR-103/107 (Figure 7E). To confirm that this extent of
miR-200 upregulation was biologically effective, we monitored
the miR-200 targets ZEB1 and ZEB2. We found that these genes
were downregulated (Figure 7F) in antagomiR-103/107-treated
cells to about 50%, mimicking the effect of mature miR-200
overexpression (see Figure 7I). In agreement, we found that5–1207, June 25, 2010 ª2010 Elsevier Inc. 1203
Figure 7. The miR-200 Family Members Are
Inhibited by miR-103/107 to Promote Mesen-
chymal Traits
(A) A model for the miR-103/107-Dicer-miR-200 pathway
in EMT control.
(B and C) Transfection of miR-200b reverts the EMT
induced by pri-miR-107 in NMuMG, as assayed by cell
morphology (B) and by qRT-PCR for the expression of
epithelial (E-cadherin) or mesenchymal markers (vimentin,
ZEB1, and ZEB2) (C). Graphs show relative expression
levels.
(D) Transwell migration assays of MDA-MB-231 cells
treated with antagomiR-103/107, alone or in combination
with a mix of antagomiRs targeting the entire miR-200
family (antagomiR-200). AntagomiR-MUT serves as
negative control. Depletion of miR-103/107 inhibits
MDA-MB-231 cell migration but has no effect in cells
depleted of the miR-200 family. See Figure S6A for
controls of antagomiR-200 effects.
(E–H) miR-103/107 regulate the expression and activity of
the miR-200 family.
(E) Expression of mature miR-200 family members
(miR-429,miR-200b, andmiR-200c) in MDA-MB-231 cells
treated as in (D). Graphs show quantification of gene
expression by qRT-PCR. For each marker, expression
values were given as relative to those of antagomiR-
MUT-treated cells.
(F) qRT-PCR analysis for the expression of the miR-200
direct targets ZEB1 and ZEB2 in MDA-MB-231 cells
treated with antagomiR-MUT or antagomiR-103/107.
(G and H) Panels show qRT-PCR for mature miR-200
family members (G) and for their targets ZEB1 and ZEB2
(H) in MDA-MB-231 cells transiently transfected with
miR-107-MUT or miR-107. Coexpression of a miR-insen-
sitive form of Dicer transgene opposes the effects of
miR-107. See Figure S6B for pre-miRNA levels upon
miR-107 transfection.
(I and J) Forced expression of miR-200b inhibits the
effects of gain of mir-107 on gene expression and cell
migration. MDA-MB-231 cells were transiently transfected
with the indicated combinations of miRNAs and assayed
for ZEB2 expression by qRT-PCR (I) or for cell migration
by transwell assay (J).
Data are shown as mean and SD. See also Figure S6.
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overexpression ofmiR-107 downregulatesmiR-200 and upregu-
lates ZEB1 and ZEB2 mRNA levels (Figures 7G and 7H). Impor-
tantly, these effects are potently rescued by adding-back Dicer
(Figures 7G and 7H). Crucially, expression of miR-200 blocks
the phenotypic effects of miR-107, as assayed by expression
of ZEB2 and cell migration (Figures 7I and 7J), indicating that
inhibition of miR-200 is critical for maintenance of mesenchymal
and motile properties by the miR-103/107-Dicer axis.DISCUSSION
ThemiR-103/107-Dicer Connection in Metastasis
The findings here presented provide evidence that cancer cells
use global downregulation of the miRNA network to induce
epithelial plasticity and foster invasive and metastatic behaviors.
In breast cancer, a microRNA targeting Dicer, miR-103/107,
plays a causal role in these events.
These data contribute to an unsettled issue in cancer biology.
Genetically, as revealed by knockout of Dicer or Drosha in mice,
miRNA biosynthesis is essential for basic cellular functions, such
as stemness, cell-cycle progression, and mitosis (Bernstein
et al., 2003; Fukagawa et al., 2004; Tang et al., 2007); these
processes are ostensibly essential at all stages of tumorigenesis.
Despite this, global downregulation of miRNA expression and
processing appears a widespread phenomenon in cancer (Lu
et al., 2005; Ozen et al., 2008; Ventura and Jacks, 2009). These
observations beg the question of how cancer cells can seam-
lessly reconcile to lose miRNA activity without tackling cellular
basal functions.
This study unveils a means by which breast cancer cells solve
this dilemma. We find that in metastatic cells, high levels of
miR-103/107 attenuate Dicer expression: this empowers inva-
sive and metastatic properties without major impact on primary
tumor growth. Thus, it appears that distinct cellular functions are
differentially sensitive to Dicer fluctuations. mir-103/107 keep
Dicer below a threshold required for metastasis protection.
Conversely, the miRNA network sustaining tumor growth oper-
ates safely at lower Dicer levels (Kumar et al., 2009). An appeal
of this system is its embedded robustness: miR-103/107 are
both generated by, and regulators of, Dicer; this mutual feed-
back relationship allows scale-down of Dicer levels but is also
intrinsically incompatible with complete depletion, maintaining
sufficient Dicer for growth control and, likely, other cellular
functions.miR-103/107 and Epithelial Plasticity
Our clinical validation studies reveal that high levels of miR-103/
107 earmark primary breast tumors with metastatic capacity. By
facilitating the acquisition of a more plastic epithelial state, the
miR-103/107-Dicer axis may assist early tumor dissemination,
preceding or conspiring with other genetic lesions that complete
neoplastic conversion or endow distant colonization. Moreover,
miRNAs have been envisioned as key players in ‘‘robustness
loops’’ that prevent aberrant/ectopic gene expression, in so
doing stabilizing cell identity and masking expression of genetic
variation (Hornstein and Shomron, 2006; Inui et al., 2010). Thus,
escaping miRNA control in cancer cells, as attained upon Dicerdownregulation, may allow the phenotypic emergence of more
aggressive genetic variants, accelerating cancer progression.
A significant finding was indeed the association of the
miR-103/107-Dicer pair with EMT. In normal tissues, the EMT
program is used to assist epithelial plasticity whereas it is
exploited opportunistically in cancer to habilitate metastasis
(Polyak and Weinberg, 2009). Thus, the ability of miR-103/107
to turn on this program may well represent a leading mechanism
by which miR-103/107 foster breast cancer metastasis.
It is worth discussing why only EMT becomes manifest
after the general downregulation of miRNAs induced by the
miR-103/107-Dicer axis. For several biological processes,
downregulation of miRNAs might not reveal immediate pheno-
typic consequences in virtue of the ‘‘balancing effect’’ between
miRNAs favoring and opposing the same process, keeping the
system in equilibrium; for example, increase of miR-103/107
downregulates miRNAs playing both positive (i.e., miR-1792
cluster ormiR-21) and negative (i.e., let-7 family) effects on prolif-
eration (Ventura and Jacks, 2009). In contrast, the gene network
controlling the maintenance of the epithelial phenotype appears
mainly under positive control by miRNAs, as attested by multiple
miRNAs inhibiting EMT (miR-200a, miR-200b, miR-200c,
miR-141, miR-429, miR-205, and miR-125a) (Inui et al., 2010;
Polyak and Weinberg, 2009). Our data suggest that this imbal-
ance is exploited in breast cancer to favor acquisition of mesen-
chymal traits. Notably, leading targets of the miR-200 family are
ZEB1 and ZEB2, pivotal genes for mesenchymality (Burk et al.,
2008; Liu et al., 2008).
Additionally, the EMT bias can be also explained by the fact
that different mRNAs may display differential sensitivity to the
changes in levels of cognate miRNAs imposed by miR-103/
107. From this perspective, it’s worth noticing that miR-200
genes are transcriptionally repressed by ZEB1. This configures
an unusual double-negative circuit that magnifies fluctuations
in its components, favoring a ‘‘switch-like’’ transition between
two alternative states (i.e., epithelial versus fully mesenchymal)
(Inui et al., 2010). Indeed, we found that levels of ZEB1/ZEB2
are controlled by miR-107 in a miR-200-dependent manner
(Figures 7F and 7I). As comparison, mature miR-15/16 and
let-7 family members and miR-1792 cluster are downregulated
similarly to miR-200 by miR-107, but the steady-state levels of
some of their key targets (BCL2, KRas, and cMyc, respectively)
are not affected (Figure S6C). Clearly, our focus on EMT does
not exclude that miR-103/107 may regulate other biological
processes regulated by Dicer and miRNAs in metastatic cancer
cells or other cellular contexts.
Clinical Implications
In human primary breast tumors, we validated expression of
miR-103/107, but not Dicer mRNA, as prognostic marker. This
finding is consistent with miR-103/107 targeting Dicer transla-
tion; this endows miR-103/107 with a better patient stratification
capacity than Dicer transcripts. That said, tumors may regulate
Dicer by other means, including genetic inactivation; indeed
low levels of Dicer are associated with poor survival in a fraction
of lung and ovarian cancer patients and animal models (Kumar
et al., 2009; Karube et al., 2005; Merritt et al., 2008). Here we
found that, similarly to elevated miR-103/107, heterozygousCell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc. 1205
loss of Dicer also instills metastatic propensity in breast cancer
patients. Likely, this result is not apparent from the analysis of
Dicer mRNA levels because this genetic lesion occurs in a rela-
tively minor fraction of patients, complicating in large datasets
the assignments of reliable cutoff values for patients’ correla-
tions. It is tempting to speculate that the use of a miR-103/107
may be preferred over genetic deletion because it may represent
a reversible and dynamic means to attenuate Dicer protein
levels, perhaps corresponding to a physiological process
requiring transient empowering of cell motility (i.e., during
wound-healing or neural crest biology).
Finally, our findings have some implications for treatment of
breast cancer. The positive effects of antagomiR-103/107 in
our experimental models of metastasis at least suggest that
modulation of miR-103/107 by RNA-based therapeutics may
prove clinically useful.EXPERIMENTAL PROCEDURES
Biological Assays in Mammalian Cells
For Transfection procedures and luciferase assays, see the Extended
Experimental Procedures and Martello et al., 2007. For wound-healing exper-
iments, cells were plated in 6-well plates, transfected as indicated, and
cultured to confluency. Cells were serum-starved and scraped with a P200
tip (time 0), and the number of migrating cells were counted from pictures
(five fields) taken at the indicated time points.
Transwell migration/invasion assays were performed in 24-well PET inserts
(Costar 8.0 mm pore size). Cells were plated and transfected with miRNA as
indicated. The day after, 100.000 cells were plated in serum-free media in
transwell inserts (at least three replicas for each sample). Medium containing
1% FBS served as chemoattractant in the lower chamber. Cells in the upper
part of the transwell were removed with a cotton swab; migrated cells were
fixed in 4% PFA and stained with 0.5% Crystal Violet. Filters were photo-
graphed and the total number of cells counted. Each experiment was repeated
at least three times independently.
For Dicer knockdown the sequences of the siRNA were: 50-UCC AGA GCU
GCU UCA AGC ATT-30 and 50-UGC UUG AAG CAG CUC UGG ATT-30. As for
mature miRNAs: miR-107: 50-AGC AGC AUU GUA CAG GGC UAU CA-30 and
50-AUA GCC CUG UAC AAU GCU GCC UU-30; miR-107-MUT: 50-AUA GCC
CUG UAC AuU cCg GaC UU-30 and 50-AuC cGg AaU GUA CAG GGC UAU
CA-30; miR-200b: 50-AUC AUU ACC AGG CAG UAU UAG A-30 and 50-UAA
UAC UGC CUG GUA AUG AUG A-30.Experimental Models of Metastasis and AntagomiR-Treatment
Mice were housed in Specific Pathogen Free (SPF) animal facilities and treated
in conformity with institutional guidelines. For xenograft studies of breast
cancer metastasis, cells (500.000 cells/mouse for 4T1 cells, 1.000.000 cells/
mouse for SUM149 cells) were unilaterally injected into the mammary fat
pad, or in the tail vein, of SCID female mice, age-matched between 5 and
7 weeks. After the indicated periods, mice were sacrificed and their lungs
explanted for histological analyses.
AntagomiRswere designedasdescribed (Krutzfeldt et al., 2005)andpurchased
from Fidelity System. Sequences were ‘‘AntagomiR-103/107’’: 50-U*U*CAU
AGCCCUGUACAAUGCUG*C*U*U*-Chol-30; ‘‘AntagomiR-MUT’’: 50-U*U*CAUAa
CCCUGUAaAAUcaUc*a*U*U*-Chol-30; ‘‘AntagomiR-200a’’: 50-G*A*ACATCGT
TACCAGCCAGTGT*T*A*G*-Chol-30; ‘‘AntagomiR-200b’’: 50-C*C*C ATCCTTA
CCCGGCAG TCTT*A*G *A*-Chol-30; all the bases are 20-OMe modified, * repre-
sents a phosphorothioate linkage, and ‘‘Chol’’ represents linked cholesterol tail.
For AntagomiR-200 we used a 1:1 mixture of the two oligos.
4T1 cells, after 4 days of AntagomiR treatment, were orthotopical injected in
SCID mice (500.000 cells/mouse). After 3 days, 100 ml of AntagomiR-103/107
or control AntagomiR-MUT solutions (diluted in PBS at 2 mg/ml) were injected
intratumorally three times per week for 2 weeks.1206 Cell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at doi:10.
1016/j.cell.2010.05.017.
ACKNOWLEDGMENTS
This work is supported by Cariparo Foundation Excellence-grant and
Carimodena Foundation international grants to S.B., and AIRC, University of
Padua Strategic-grant, Cariparo Foundation Excellence-grant, IIT (Italian Insti-
tute of Technology), and Telethon grants to S.P., and ISSN ‘‘Giovani Ricerca-
tori’’ to G.M. We thank T. Rodriguez, O. Wessely, and D. Volpin for comments
on the manuscript; the anonymous reviewers for thoughtful directions; and S.
Bobisse and R. Venerando for help with cytofluorimeter. We are grateful to
colleagues for gifts of reagents: L. Naldini (lentiviral vectors), T. Jacks (mouse
shDicer plasmid), P. Provost (Dicer cDNA), W. Filipowicz (Dicer antibody),
R. Agami (miR-Vec), F. Miller (4T1 cells), G. Hannon (Dicer null cells), and
R. Weinberg (SUM149 cells).
Received: August 21, 2009
Revised: February 23, 2010
Accepted: April 14, 2010
Published: June 24, 2010
REFERENCES
Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 350–355.
Aslakson, C.J., and Miller, F.R. (1992). Selective events in the metastatic
process defined by analysis of the sequential dissemination of subpopulations
of a mouse mammary tumor. Cancer Res. 52, 1399–1405.
Bartel, D.P. (2009). MicroRNAs: target recognition and regulatory functions.
Cell 136, 215–233.
Baskerville, S., and Bartel, D.P. (2005). Microarray profiling of microRNAs
reveals frequent coexpression with neighboring miRNAs and host genes.
RNA 11, 241–247.
Bernstein, E., Kim, S.Y., Carmell, M.A., Murchison, E.P., Alcorn, H., Li, M.Z.,
Mills, A.A., Elledge, S.J., Anderson, K.V., and Hannon, G.J. (2003). Dicer is
essential for mouse development. Nat. Genet. 35, 215–217.
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S.,
and Brabletz, T. (2008). A reciprocal repression between ZEB1 and members
of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep.
9, 582–589.
Calin, G.A., and Croce, C.M. (2006). MicroRNA signatures in human cancers.
Nat. Rev. Cancer 6, 857–866.
Charafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti,
P., Hur, M.H., Diebel, M.E., Monville, F., Dutcher, J., et al. (2009). Breast cancer
cell lines contain functional cancer stem cells with metastatic capacity and
a distinct molecular signature. Cancer Res. 69, 1302–1313.
Filipowicz, W., Bhattacharyya, S.N., and Sonenberg, N. (2008). Mechanisms of
post-transcriptional regulation by microRNAs: are the answers in sight? Nat.
Rev. Genet. 9, 102–114.
Friedman, R.C., Farh, K.K., Burge, C.B., and Bartel, D.P. (2009). Most mamma-
lian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105.
Fukagawa, T., Nogami, M., Yoshikawa, M., Ikeno, M., Okazaki, T., Takami, Y.,
Nakayama, T., and Oshimura, M. (2004). Dicer is essential for formation of
the heterochromatin structure in vertebrate cells. Nat. Cell Biol. 6, 784–791.
Hornstein, E., and Shomron, N. (2006). Canalization of development by
microRNAs. Nat. Genet. Suppl. 38, S20–S24.
Inui, M., Martello, G., and Piccolo, S. (2010). microRNA control of signal
transduction. Nat. Rev. Mol. Cell Biol. 11, 252–263.
Karube, Y., Tanaka, H., Osada, H., Tomida, S., Tatematsu, Y., Yanagisawa, K.,
Yatabe, Y., Takamizawa, J., Miyoshi, S., Mitsudomi, T., et al. (2005). Reduced
expression of Dicer associated with poor prognosis in lung cancer patients.
Cancer Sci. 96, 111–115.
Krek, A., Grun, D., Poy, M.N., Wolf, R., Rosenberg, L., Epstein, E.J.,
MacMenamin, P., da Piedade, I., Gunsalus, K.C., Stoffel, M., et al. (2005).
Combinatorial microRNA target predictions. Nat. Genet. 37, 495–500.
Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan,
M., and Stoffel, M. (2005). Silencing of microRNAs in vivo with ‘antagomirs’.
Nature 438, 685–689.
Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R., and Jacks, T. (2007). Impaired
microRNA processing enhances cellular transformation and tumorigenesis.
Nat. Genet. 39, 673–677.
Kumar, M.S., Pester, R.E., Chen, C.Y., Lane, K., Chin, C., Lu, J., Kirsch, D.G.,
Golub, T.R., and Jacks, T. (2009). Dicer1 functions as a haploinsufficient tumor
suppressor. Genes Dev. 23, 2700–2704.
Leibovitz, A., Stinson, J.C., McCombs, W.B., 3rd, McCoy, C.E., Mazur, K.C.,
and Mabry, N.D. (1976). Classification of human colorectal adenocarcinoma
cell lines. Cancer Res. 36, 4562–4569.
Liu, Y., El-Naggar, S., Darling, D.S., Higashi, Y., and Dean, D.C. (2008). Zeb1
links epithelial-mesenchymal transition and cellular senescence. Development
135, 579–588.
Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-
Cordero, A., Ebert, B.L., Mak, R.H., Ferrando, A.A., et al. (2005). MicroRNA
expression profiles classify human cancers. Nature 435, 834–838.
Ma, L., Teruya-Feldstein, J., and Weinberg, R.A. (2007). Tumour invasion and
metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682–688.Martello, G., Zacchigna, L., Inui, M., Montagner, M., Adorno, M., Mamidi, A.,
Morsut, L., Soligo, S., Tran, U., Dupont, S., et al. (2007). MicroRNA control
of Nodal signalling. Nature 449, 183–188.
Merritt, W.M., Lin, Y.G., Han, L.Y., Kamat, A.A., Spannuth, W.A., Schmandt,
R., Urbauer, D., Pennacchio, L.A., Cheng, J.F., Nick, A.M., et al. (2008). Dicer,
Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359,
2641–2650.
Miettinen, P.J., Ebner, R., Lopez, A.R., and Derynck, R. (1994). TGF-beta
induced transdifferentiation of mammary epithelial cells to mesenchymal cells:
involvement of type I receptors. J. Cell Biol. 127, 2021–2036.
Ozen, M., Creighton, C.J., Ozdemir, M., and Ittmann, M. (2008). Widespread
deregulation of microRNA expression in human prostate cancer. Oncogene
27, 1788–1789.
Polyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and
mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev.
Cancer 9, 265–273.
Tang, F., Kaneda, M., O’Carroll, D., Hajkova, P., Barton, S.C., Sun, Y.A., Lee,
C., Tarakhovsky, A., Lao, K., and Surani, M.A. (2007). Maternal microRNAs are
essential for mouse zygotic development. Genes Dev. 21, 644–648.
Ventura, A., and Jacks, T. (2009). MicroRNAs and cancer: short RNAs go
a long way. Cell 136, 586–591.
Volinia, S., Calin, G.A., Liu, C.G., Ambs, S., Cimmino, A., Petrocca, F., Visone,
R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006). A microRNA expression
signature of human solid tumors defines cancer gene targets. Proc. Natl.
Acad. Sci. USA 103, 2257–2261.Cell 141, 1195–1207, June 25, 2010 ª2010 Elsevier Inc. 1207
